Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: Therapeutic implications

被引:27
|
作者
Michiels, Jan J.
Berneman, Zwi
Gadisseur, Alain
van der Planken, Marc
Schroyens, Wilfried
Budde, Ulrich
van Viiet, Huub H. D. M.
机构
[1] Univ Antwerp Hosp, Dept Hematol, Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Biol Clin, Lab Hemostasis & Hematol, Antwerp, Belgium
[3] Coagulat Lab, Hamburg, Germany
[4] Erasmus MC, Rotterdam, Netherlands
[5] Hemostasis Thrombosis & Vasc Res Ctr, Goodheart Inst, Rotterdam, Netherlands
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2006年 / 32卷 / 06期
关键词
acquired von Willebrand syndrome (AvWS); systemic lupus erythematosus; monoclonal gammopathy; hypothyroidism; Wilms' tumor; thrombocythemia; diagnosis; treatment;
D O I
10.1055/s-2006-949663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most common nonimmune etiology of acquired von Willebrand syndrome (AvWS) includes hypothyroldism, Wilms' tumor, thrombocythemia, or congenital heart defects, and the use of various drugs. AvWS type 1 in patients with hypothyroidism is due to decreased Willebrand factor (vWF) synthesis and is reversible by treatment with thyroxin. AvWS type 1 or 3 in children with Wilms' tumor disappears after successful chemotherapy or tumor resection but the mechanism of the vWF deficiency is unknown. The AvWS type 2 in patients with thrombocythemia of various myeloproliferative disorders is caused by increased proteolysis of large vWF multimers at increasing platelet counts to above 1000 x 10(9)/L. Reduction of platelet counts to normal results in correction of the vWF parameters together with disappearance of the bleeding tendency. Type 2-like AvWS in children with congenital heart valve defects is caused by shear stress-induced proteolysis of large vWF multimers and is reversible after surgical correction. AvWS associated with the use of drugs disappears after discontinuation of the causative agent. Immune-mediated AvWS is associated with either systemic lupus erythernatosus (SLE) or immunoglobulin G (IgG) benign monoclonal gammopathy (BMG), and usually shows a type 2 vWF deficiency. Using a simple enzyme-linked immunosorbent assay, an IgG antibody against vWF is detectable in AvWS associated with SLE and IgG BMG. The IgG-autoantibodrfactor (F) vWF/VIII complex is rapidly cleared from the circulation, which explains the combined FVIII:coagulant activity (C) and vWF deficiency and the poor responses of FVIII:C and vWF parameters to intravenous desmopressin acetate and vWF/FVIII concentrates. A transient correction of both FVIII:C and vWF parameters to normal for a few weeks after high-dose intravenous immunoglobulin is seen in AvWS associated with SLE and IgG BMG. AvWS associated with SLE uniformly shows a curative response to corticosteroids. AvWS associated with IgG BMG does not respond to corticosteroids, immune suppression, or chemotherapy. AvWS associated with IgM BMG is rare and does not respond to any conventional treatment.
引用
收藏
页码:577 / 588
页数:12
相关论文
共 50 条
  • [1] Therapeutic algorithm for patients with acquired von Willebrand syndrome and monoclonal gammopathy
    Staritz, P.
    Krause, M.
    Zimmermann, R.
    Huth-Kuehne, A.
    HAEMOPHILIA, 2010, 16 : 154 - 154
  • [2] Therapeutic algorithm for patients with acquired von Willebrand syndrome and monoclonal gammopathy
    Staritz, P.
    Lages, P.
    Krause, M.
    Zimmermann, R.
    Huth-Kuehne, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 206 - 206
  • [3] Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus
    Alam, Sara Taveras
    Alexis, Karenza
    Sridharan, Ashwin
    Strakhan, Marianna
    Elrafei, Tarek
    Gralla, Richard J.
    Reed, Louis J.
    CASE REPORTS IN HEMATOLOGY, 2014, 2014
  • [4] Systemic lupus erythematosus complicated by acquired von Willebrand's syndrome
    Hong, S. C.
    Lee, J. H.
    Chi, H. S.
    Lee, C. K.
    Nah, S. S.
    Kim, Y. G.
    Oh, J. S.
    Moon, H. B.
    Yoo, B.
    LUPUS, 2008, 17 (09) : 846 - 848
  • [5] Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus
    Stufano, Francesca
    Baronciani, Luciano
    Biguzzi, Eugenia
    Cozzi, Giovanna
    Colpani, Paola
    Chisini, Marta
    Peyvandi, Flora
    HAEMOPHILIA, 2019, 25 (01) : E30 - E32
  • [6] Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance
    Toshiaki Yujiri
    Yukinori Nakamura
    Isamu Oota
    Kaori Nakano
    Yukio Tanizawa
    Annals of Hematology, 2014, 93 : 1427 - 1428
  • [7] Acquired von Willebrand syndrome in systemic lupus erythematodes
    Michiels, JJ
    Schroyens, W
    van der Planken, M
    Berneman, Z
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2001, 7 (02) : 106 - 112
  • [8] 4 CASES OF ACQUIRED VON WILLEBRAND SYNDROME IN ASSOCIATION WITH MONOCLONAL GAMMOPATHY
    HORELLOU, MH
    BAUMELOU, E
    SITBON, N
    MARIE, JP
    CONARD, J
    DECARBONNIERES, C
    GORIN, NC
    ZITTOUN, R
    SAMAMA, M
    ANNALES DE MEDECINE INTERNE, 1983, 134 (08): : 707 - 712
  • [9] Acquired von Willebrand syndrome in a patient with monoclonal gammopathy of undetermined significance
    Puronen, Camille E.
    Josephson, Neil C.
    Broudy, Virginia C.
    BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (04) : 430 - 432
  • [10] Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance
    Yujiri, Toshiaki
    Nakamura, Yukinori
    Oota, Isamu
    Nakano, Kaori
    Tanizawa, Yukio
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1427 - 1428